Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- PMID: 24355989
- DOI: 10.1038/nrm3722
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Abstract
The BCL-2 protein family determines the commitment of cells to apoptosis, an ancient cell suicide programme that is essential for development, tissue homeostasis and immunity. Too little apoptosis can promote cancer and autoimmune diseases; too much apoptosis can augment ischaemic conditions and drive neurodegeneration. We discuss the biochemical, structural and genetic studies that have clarified how the interplay between members of the BCL-2 family on mitochondria sets the apoptotic threshold. These mechanistic insights into the functions of the BCL-2 family are illuminating the physiological control of apoptosis, the pathological consequences of its dysregulation and the promising search for novel cancer therapies that target the BCL-2 family.
Similar articles
-
Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.Clin Exp Pharmacol Physiol. 2004 Mar;31(3):119-28. doi: 10.1111/j.1440-1681.2004.03975.x. Clin Exp Pharmacol Physiol. 2004. PMID: 15008953 Review.
-
Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.J Biol Chem. 2013 Mar 8;288(10):7387-98. doi: 10.1074/jbc.M112.400754. Epub 2013 Jan 11. J Biol Chem. 2013. PMID: 23316052 Free PMC article.
-
Targeting the BH3 domain of Bcl-2 family proteins. A brief history from natural products to foldamers as promising cancer therapeutic avenues.Curr Med Chem. 2013;20(24):2964-78. doi: 10.2174/0929867311320240003. Curr Med Chem. 2013. PMID: 23746270 Review.
-
[The Bcl-2 family of proteins as drug targets].J Soc Biol. 2005;199(3):253-65. doi: 10.1051/jbio:2005027. J Soc Biol. 2005. PMID: 16471266 Review. French.
-
The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update.Arch Toxicol. 2015 Mar;89(3):289-317. doi: 10.1007/s00204-014-1448-7. Epub 2015 Jan 25. Arch Toxicol. 2015. PMID: 25618543 Review.
Cited by
-
Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.BMC Cancer. 2024 Nov 4;24(1):1350. doi: 10.1186/s12885-024-13088-7. BMC Cancer. 2024. PMID: 39497108 Free PMC article.
-
A Novel Imidazopyridine Derivative Exerts Anticancer Activity by Inducing Mitochondrial Pathway-Mediated Apoptosis.Biomed Res Int. 2020 Aug 25;2020:4929053. doi: 10.1155/2020/4929053. eCollection 2020. Biomed Res Int. 2020. PMID: 32908894 Free PMC article.
-
Synergistic integration of metal nanoclusters and biomolecules as hybrid systems for therapeutic applications.Acta Pharm Sin B. 2021 May;11(5):1175-1199. doi: 10.1016/j.apsb.2020.12.004. Epub 2020 Dec 15. Acta Pharm Sin B. 2021. PMID: 34094827 Free PMC article. Review.
-
Armeniacae semen amarum: a review on its botany, phytochemistry, pharmacology, clinical application, toxicology and pharmacokinetics.Front Pharmacol. 2024 Jan 23;15:1290888. doi: 10.3389/fphar.2024.1290888. eCollection 2024. Front Pharmacol. 2024. PMID: 38323080 Free PMC article. Review.
-
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.Oncotarget. 2016 May 10;7(19):27946-58. doi: 10.18632/oncotarget.8547. Oncotarget. 2016. PMID: 27056887 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources